RIBB

Ribbon Acquisition Corp. (RIBB) - Form 8-K Summary

Business Context and Reporting Period

Date: September 2, 2026
Company: Ribbon Acquisition Corp. (Cayman Islands exempted company)
Event: Entry into material definitive agreements in connection with a proposed Business Combination with DRC Medicine Ltd. (Target) and the formation of DRC Medicine Inc. (PubCo).
Counterparty: Meteora Select Trading Opportunities Master, LP (Investor).

Key Financial Metrics and Transaction Terms

This filing details financing arrangements rather than historical operating results. Key financial terms include:

• Forward Purchase Agreement: Investor to purchase up to 4,100,000 shares of PubCo common stock at the Initial Price (per-share redemption price). Settlement occurs six months post-closing based on volume-weighted average price, net of a $1.00 adjustment per share.
• Standby Equity Purchase Agreement (SEPA): Commitment to purchase up to $100,000,000 of shares over 36 months at 97% of the market price. No minimum usage requirement.
• Commitment Fee: 1.75% of the SEPA commitment ($1,750,000), payable in two installments in cash or shares.
• Convertible Promissory Note: Initial principal of $1,212,121 funded by a $1,000,000 payment (17.5% original issue discount). Matures 12 months post-closing. Bears no interest unless in default (18% per annum). Subject to a 7% payment premium on redemption.
• Expense Reimbursement: Up to $80,000 for legal and transaction expenses, payable in cash or capitalized into the Note at 150% of the unpaid amount.
• Escrow Collateral: 9.9% of PubCo's outstanding shares to be deposited in escrow as security for the Note.

Material Changes and Agreements

The filing reports the execution of five new agreements on September 2, 2026, which are contingent upon the closing of the Business Combination:

1. Forward Purchase Agreement: Establishes a prepaid forward transaction with a reference price of $10.00 for the first 30 days post-closing, resetting weekly thereafter.
2. Subscription Agreement: Allows the Investor to purchase "Additional Shares" to fulfill the Forward Purchase Agreement, subject to a 9.9% beneficial ownership cap.
3. SEPA: Provides a liquidity backstop with a 19.99% exchange cap and 4.9% beneficial ownership limitation for the Investor.
4. Convertible Note: Includes a mandatory prepayment provision requiring 33% of net proceeds from future financings to be applied to the Note principal.
5. Registration Rights: Requires filing of a resale registration statement within 30 days of closing. Failure to do so triggers monthly liquidated damages of 2% of the Note principal (capped at 24%).

Outlook, Risks, and Contingencies

Management Commentary & Outlook: The transactions are designed to support the post-merger entity (PubCo) with liquidity and a mechanism for the Investor to acquire equity. The Investor holds a right of first refusal on up to 33% of future financings.

Risks and Contingencies:

• Closing Conditions: All agreements are subject to the successful consummation of the Business Combination, shareholder approval, and satisfaction of closing conditions.
• Redemption Risk: The Initial Price is tied to the redemption price payable to redeeming shareholders, creating variability in the cost of the Forward Purchase Agreement.
• Default Consequences: An event of default under the Note results in the transfer of escrowed shares (9.9% of outstanding stock) to the Investor as partial liquidated damages.
• Registration Failure: Failure to maintain an effective registration statement constitutes a default under the Note.

Investor Verification Checklist

• Verify the final redemption price per share to determine the "Initial Price" for the Forward Purchase Agreement and Subscription Agreement.
• Confirm the status of the Business Combination vote and whether the transaction has closed as of the current date.
• Review the definitive proxy statement/prospectus (Form S-4) for details on the Target (DRC Medicine Ltd.) and the pro forma capitalization.
• Monitor the filing of the resale registration statement required within 30 days of closing to avoid Note default penalties.
• Assess the impact of the 33% mandatory prepayment of future financing proceeds on the Company's ability to raise additional capital.